Otonomy to Participate in the H.C. Wainwright Global Investment Conference
Otonomy, Inc. (Nasdaq: OTIC) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Otonomy, Inc. (Nasdaq: OTIC) announced its participation in the H.C. Wainwright Global Investment Conference, set to take place on May 24, 2022. A pre-recorded presentation by the management team will be accessible at 7 a.m. ET / 4 a.m. PT on the conference website. Additionally, a link will be available on Otonomy's Events page. The company specializes in innovative therapeutics for neurotology, particularly in addressing hearing loss and tinnitus through advanced drug delivery technology.
Details
News Market Reaction – OTIC
The recorded move for OTIC in the trading session of this news was -5.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022.
A link to the presentation will also become available at the same time through the Events page of the company's website (www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries
Spectrum Science
Lauren Benton
Senior Account Executive
212.899.9731
lbenton@spectrumscience.com
Investor Inquiries:
ICR Westwicke
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.